Cetek Corporation and Cubist Pharmaceuticals Expand Collaboration.Business Editors &Health/Medical Writers
MARLBOROUGH, Mass.--(BW HealthWire)--Jan. 20, 2000
Cetek Corporation announced today the signing of a collaboration with Cubist Pharmaceuticals (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CBST CBST Center for Biophotonics Science and Technology
CBST Congregation Beth Simcha Torah (NYC)
CBST Complete Binary Search Tree ) for the development of novel, anti-infective high throughput screening assays. Under the agreement, Cetek will develop their capillary electrophoresis Capillary electrophoresis (CE), also known as capillary zone electrophoresis (CZE), can be used to separate ionic species by their charge and frictional forces. In traditional electrophoresis, electrically charged analytes move in a conductive liquid medium under the (CE) assays for a proprietary Cubist target and will screen the assays against Cubist's compound libraries. The parties have previously completed a pilot study research project.
&uot;We began working with Cetek earlier this year and found that their technology complements our VITA(TM) technology and allows us to pursue additional anti-infective targets,&uot; said Dennis Keith, Ph.D., Vice President, Drug Discovery at Cubist. &uot;We expect that Cetek's fast assay development will quickly provide us results on the binding of small molecules to novel new targets.&uot;
&uot;Working with Cubist has allowed us to expand our technology into new assay formats for high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method ,&uot; said Dr. Dallas Hughes, Vice President, Technology at Cetek. &uot;We are pleased to be collaborating with Cubist in helping them find high quality, small molecule drug candidates for discovery and development.&uot;
Cubist's VITA(TM) technology generates functional biology data useful for prioritizing the most valuable protein therapeutic targets from clinically important pathogens such as Staphylococcus aureus Staphylococcus au·re·us
A bacterium that causes furunculosis, pyemia, osteomyelitis, suppuration of wounds, and food poisoning.
Staphylococcus aureus Staphylococcus pyogenes and Escherichia coli Escherichia coli (ĕsh'ərĭk`ēə kō`lī), common bacterium that normally inhabits the intestinal tracts of humans and animals, but can cause infection in other parts of the body, especially the urinary tract. for the discovery of new anti-infectives. Macromolecules Macromolecules
A large molecule composed of thousands of atoms.
Mentioned in: Gene Therapy
macromolecules that bind to functionally relevant sites on a target are used to validate the target for drug discovery and serve as tools for high throughput competitive binding assays com·pet·i·tive binding assay
An assay in which a biologically specific binding agent competes for radioactively labeled or unlabeled compounds, used especially to measure the concentration of hormone receptors in a sample by introducing a to identify quality, small molecule leads for medicinal chemistry programs. VITA(TM) is broadly applicable to the in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body.
Within a living organism.
in vivo adv. validation and screening of a number of different targets, including proteins encoded by open reading frames (ORFs),
which have previously been intractable to traditional screening paradigms.
Founded in 1996, Cetek Corporation has developed a new technology that can rapidly develop newly discovered targets into a high-throughput screening format. This approach enhances the ability to quickly discover valuable &uot;hits&uot; in synthetic libraries, combinatorial mixtures, and natural product extracts. The technology was originally developed at the Barnett Institute of Northeastern University by Dr. Hughes and Prof. Barry Karger and is licensed exclusively to Cetek. This proprietary technology combines laser-induced fluorescence or UV detection with high resolution CE.
Cetek focuses on collaborating with leading pharmaceutical and biotechnology companies to derive benefits from this powerful screening technology. The company is a privately held drug discovery company with laboratories located in Marlborough, MA.
For additional information, visit the Companies Internet web sites at http://www.cetek.com or at http://www.cubist.com or contact Dr. James N. Little, Senior Vice President, at (508) 229-8900 or email@example.com.